Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals
dc.contributor.author | Davies, M | |
dc.contributor.author | Bramwell, LR | |
dc.contributor.author | Jeffery, N | |
dc.contributor.author | Bunce, B | |
dc.contributor.author | Lee, BP | |
dc.contributor.author | Knight, B | |
dc.contributor.author | Auckland, C | |
dc.contributor.author | Masoli, JA | |
dc.contributor.author | Harries, LW | |
dc.date.accessioned | 2022-05-12T14:00:44Z | |
dc.date.issued | 2021-12-07 | |
dc.date.updated | 2022-05-12T13:17:30Z | |
dc.description.abstract | OBJECTIVES: This study aimed to evaluate the associations between COVID-19 severity and active viral load, and to characterize the dynamics of active SARS-CoV-2 clearance in a series of archival samples taken from patients in the first wave of COVID-19 infection in the South West of the UK. METHODS: Subgenomic RNA (sgRNA) and E-gene genomic sequences were measured in a retrospective collection of PCR-confirmed SARS-CoV-2-positive samples from 176 individuals, and related to disease severity. Viral clearance dynamics were then assessed in relation to symptom onset and last positive test. RESULTS: Whilst E-gene sgRNAs declined before E-gene genomic sequences, some individuals retained sgRNA positivity for up to 68 days. 13% of sgRNA-positive cases still exhibited clinically relevant levels of virus after 10 days, with no clinical features previously associated with prolonged viral clearance times. CONCLUSIONS: Our results suggest that potentially active virus can sometimes persist beyond a 10-day period, and could pose a potential risk of onward transmission. Where this would pose a serious public health threat, additional mitigation strategies may be necessary to reduce the risk of secondary cases in vulnerable settings. | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.format.extent | 418-425 | |
dc.format.medium | Print-Electronic | |
dc.identifier.citation | Vol. 116, pp. 418-425 | en_GB |
dc.identifier.doi | https://doi.org/10.1016/j.ijid.2021.12.312 | |
dc.identifier.uri | http://hdl.handle.net/10871/129599 | |
dc.identifier | ORCID: 0000-0001-7791-8061 (Harries, Lorna W) | |
dc.identifier | ScopusID: 13805289700 (Harries, Lorna W) | |
dc.identifier | ResearcherID: D-2241-2014 | E-2369-2011 (Harries, Lorna W) | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/34890790 | en_GB |
dc.rights | © 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) | en_GB |
dc.subject | SARS-COV-2 | en_GB |
dc.subject | persistence | en_GB |
dc.subject | sgRNA | en_GB |
dc.subject | transmission | en_GB |
dc.title | Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-05-12T14:00:44Z | |
dc.identifier.issn | 1201-9712 | |
exeter.place-of-publication | Canada | |
dc.description | This is the final version. Available on open access from Elsevier via the DOI in this record | en_GB |
dc.identifier.eissn | 1878-3511 | |
dc.identifier.journal | International Journal of Infectious Diseases | en_GB |
dc.relation.ispartof | Int J Infect Dis, 116 | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_GB |
dcterms.dateAccepted | 2021-12-02 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-12-07 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-05-12T13:58:53Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-05-12T14:00:50Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)